ATLANTA, Jan. 09, 2025 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA). The lawsuit alleges that the Company’s registration statement issued in connection with its IPO was false and/or misleading because Defendants failed to disclose safety concerns related to its lead product candidate, azelaprag.
If you bought shares of BioAge on or after September 26, 2024 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/bioage-labs/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is March 10, 2025.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
